10-K: Jackson Acquisition II Reports 2025 Net Income, Seeks Merger

Jackson Acquisition Company II, a SPAC focused on healthcare, reported a net income of $9.1 million for 2025 while actively seeking its initial business combination by December 2026.

Summary

• Jackson Acquisition Company II is a blank check company incorporated on September 11, 2024, for the purpose of effecting a business combination.
• The company intends to focus its search for a target business within the healthcare services, healthcare technology, or broader healthcare industry.
• The initial public offering (IPO) closed on December 11, 2024, raising gross proceeds of $230,000,000 from 23,000,000 units sold at $10.00 per unit.
• Simultaneously, a private placement of 840,000 units at $10.00 per unit generated gross proceeds of $8,400,000.
• A total of $232,300,000 from the IPO and private placement proceeds was placed in a Trust Account for the benefit of public shareholders.
• For the year ended December 31, 2025, the company reported a net income of $9,115,597, primarily from interest earned on marketable securities held in the Trust Account.
• The company has not generated any operating revenues to date and has incurred losses from inception due to formation and operating costs.
• The company must complete its initial business combination by December 11, 2026, or it will be forced to liquidate the Trust Account.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-slightly-positive report for a SPAC. While the 'going concern' warning is standard, the strong trust account balance and experienced management team provide a solid foundation for the ongoing search for a business combination.

Positives

• The company has a substantial Trust Account balance of $242,543,188 as of December 31, 2025, providing significant capital for a business combination.
• The management team possesses extensive experience in healthcare, operations, and capital markets, which is a key competitive strength for sourcing and executing acquisitions.
• The company's strategic focus on fundamentally healthy healthcare businesses with potential for significant equity value creation and strong downside protection is a disciplined approach.
• A 30-year tax exemption undertaking from the Cayman Islands government provides a favorable tax environment.
• The company generated a net income of $9,115,597 for the year ended December 31, 2025, primarily from interest on the Trust Account, indicating effective management of its cash reserves.

Negatives

• The company faces a 'going concern' uncertainty due to the mandatory liquidation requirement if an initial business combination is not completed by December 11, 2026.
• There are no operating revenues, and the company has incurred losses since inception from formation and operating costs.
• Potential conflicts of interest exist due to the management team's and directors' other business affiliations and their ownership of founder shares, which could influence business combination decisions.
• Public shareholders may experience significant dilution if additional financing is raised through equity or convertible debt issuances to complete a business combination.
• The lack of business diversification means the company's future success will depend entirely on the performance of a single acquired business, subjecting it to concentrated risks.

Risks

• Inability to select an appropriate target business or complete an initial business combination within the specified timeframe (by December 11, 2026).
• The performance of any prospective target business may not meet expectations, leading to unsatisfactory returns.
• Challenges in retaining or recruiting key officers, employees, or directors following the initial business combination.
• Conflicts of interest may arise from officers and directors allocating their time to other businesses or having pre-existing fiduciary obligations to other entities.
• Potential inability to obtain additional financing necessary to complete an initial business combination.
• The Trust Account may become subject to claims of third parties, potentially reducing the amount available for public shareholders upon redemption.
• Public shareholders may incur material dilution due to the anti-dilution rights of founder shares or the issuance of new equity/equity-linked securities for financing.
• Acquiring a financially unstable or early-stage development business could expose the company to numerous inherent risks.
• Lack of business diversification post-combination could subject the company to significant economic, competitive, and regulatory risks.
• The assessment of a target business's management team may prove incorrect, and future management may lack public company experience.
• Shareholders may not have the ability to approve the initial business combination in all circumstances, depending on the transaction structure and applicable rules.
• The Sponsor's indemnity obligations for Trust Account claims may not be fully satisfiable if its only assets are company securities.
• Geopolitical instability (e.g., Russia-Ukraine, Israel-Hamas conflicts) could lead to market disruptions and adversely affect the search for a business combination.

Future Outlook

The company intends to focus its search for a target business in the healthcare services, healthcare technology, or broader healthcare industry, aiming to complete a business combination with a fundamentally healthy company. It expects to incur significant costs in this pursuit and may need to raise additional funds through debt or equity financing to complete an acquisition or cover operating expenditures. If a business combination is not consummated by December 11, 2026, the company will liquidate the Trust Account and dissolve.

Management Comments

• "Our management has broad discretion with respect to the specific application of the proceeds of the IPO and the Private Placement that are held out of the Trust Account, although substantially all the net proceeds are intended to be applied generally towards consummating a business combination and working capital."
• "Our goal is to complete a business combination with a company that is fundamentally healthy and then to work with that company to access the capital markets, attract experienced management talent, and execute a proprietary value-creation business plan, designed to help the company to grow into the next phase of its life cycle."
• "We plan to focus on identifying acquisition candidates to leverage our managements deep experience in the integration and coordination of healthcare services, as well as to capitalize on the current healthcare trends and valuation dislocation."
• "We plan to employ a fundamental, value-oriented acquisition framework that seeks a target with the potential for significant equity value creation coupled with strong downside protection from dependable cash flows and a durable business franchise."
• "Management plans to address this uncertainty [going concern] through debt or equity financing."

Industry Context

StockSavvy.ai notes that Jackson Acquisition Company II's strategic focus on healthcare services and technology aligns with broader industry trends of consolidation, digital transformation, and increasing demand for specialized care. The SPAC model offers a potentially faster route to public markets for target companies compared to traditional IPOs, which could be attractive in a dynamic sector like healthcare. The emphasis on "fundamentally healthy" businesses with "significant equity value creation" and "strong downside protection" suggests a disciplined approach in a competitive SPAC market.

Comparison to Industry Standards

• The filing does not provide specific comparisons to other companies, projects, or industry benchmarks. It outlines the company's internal strategy and competitive strengths based on its management team's experience and network within the healthcare sector.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material litigation or other legal proceedings.
• The company is not aware of any legal proceeding, investigation, or claim that has a more than remote possibility of having a material adverse effect on its business, financial condition, or results of operations.

Related Party Transactions

• **Founder Shares**: On September 13, 2024, the Sponsor (RJ Healthcare SPAC II, LLC) acquired 5,750,000 Class B ordinary shares for an aggregate purchase price of $25,000. On November 18, 2024, the Sponsor transferred 200,000 Founder Shares to the company's officers and directors at their original purchase price.
• **Private Placement Units**: The Sponsor purchased 495,000 Private Placement Units and Roth Capital Partners, LLC purchased 345,000 Private Placement Units, both at $10.00 per unit, generating gross proceeds of $8,400,000.
• **Promissory Note**: An unsecured promissory note was issued to the Sponsor on September 13, 2024, allowing the company to borrow up to $300,000. As of December 31, 2025, $198,024 was outstanding. The note was amended on May 7, 2025, to be payable upon consummation of an initial business combination or liquidation.
• **Administrative Services Agreement**: The company pays an affiliate of the Sponsor $10,000 per month for office space, administrative, and support services, commencing December 9, 2024. As of December 31, 2025, $127,000 was owed for these services.
• **Working Capital Loans**: The Sponsor, officers, directors, or their affiliates may loan funds up to $1,500,000 to finance transaction costs, convertible into units at $10.00 per unit. No amounts were outstanding as of December 31, 2025.
• **Indemnification Agreements**: The company has entered into agreements with its directors and officers to provide contractual indemnification.

Stakeholder Impact

• **Shareholders**: Public shareholders have redemption rights for their shares upon completion of a business combination or liquidation, but face potential dilution from future equity raises and the risk of their rights expiring worthless if no business combination occurs.
• **Sponsor**: The Sponsor risks losing its entire investment in founder shares and private placement units if a business combination is not completed by the deadline. It also has indemnity obligations for certain claims against the Trust Account.
• **Management/Directors**: Management and directors have potential conflicts of interest due to their other business affiliations and compensation structures tied to the completion of a business combination. They are reimbursed for out-of-pocket expenses.
• **Creditors**: While the company seeks waivers from vendors and service providers, there is no guarantee that all claims against the Trust Account will be waived or unenforceable, potentially impacting the funds available for public shareholders.

Next Steps

• Identify and evaluate suitable acquisition transaction candidates, focusing on the healthcare industry.
• Conduct thorough due diligence on prospective target businesses.
• Structure, negotiate, and complete an initial business combination by December 11, 2026.
• Potentially seek additional financing (debt or equity) to fund a business combination or working capital needs.
• If no business combination is completed by December 11, 2026, the company will cease operations, redeem public shares, and liquidate the Trust Account.

Key Dates

Recommendation

As a blank check company, Jackson Acquisition Company II's value is primarily tied to its ability to identify and successfully complete a business combination. The current filing is a standard annual report for a SPAC in its pre-acquisition phase, providing expected financial results (interest income, administrative expenses) and reiterating its search strategy and deadline. There is no new information that would warrant a 'buy' or 'sell' recommendation at this stage; investors are holding based on the potential for a future acquisition. The 'going concern' disclosure is typical for SPACs and does not indicate an immediate change in prospects.

Keywords

SPAC, healthcare acquisition, blank check company, business combination, JACS, SEC filing, 10-K, financial reporting, corporate governance, risk management